Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

OmniScience's clinical trial genAI-powered control tower, Vivo, wins 1st place in the CNS Summit 2024 Innovation Showcase


News provided by

OmniScience

Nov 26, 2024, 10:55 ET

Share this article

Share toX

Share this article

Share toX

Michael Bell, PhD, VP of Product at OmniScience, presents at the 2024 CNS Summit Innovation Showcase, highlighting how Vivo tackles the data challenges of clinical trials with genAI-driven insights
Michael Bell, PhD, VP of Product at OmniScience, presents at the 2024 CNS Summit Innovation Showcase, highlighting how Vivo tackles the data challenges of clinical trials with genAI-driven insights

OmniScience was awarded top honors at the 2024 Innovation Showcase for its groundbreaking solution, Vivo - a market-first solution poised to transform clinical trial operation teams' day-to-day workflow and ability to optimize trial insights with genAI

HOUSTON, Nov. 26, 2024 /PRNewswire-PRWeb/ -- The CNS Summit (Collaborating for Novel Solutions) was founded in 2010 by life sciences leaders devoted to discovering better, more efficient ways to advance the life sciences industry through innovation, collaboration, and technology.

At the November 2024 CNS Summit in Boston, OmniScience was awarded top honors at the Innovation Showcase for its groundbreaking solution, Vivo - a market-first solution poised to transform clinical trial operation teams' day-to-day workflow and ability to optimize trial insights with genAI.

Patients are waiting: The CNS Summit brings together life sciences leaders who aren't afraid to challenge the status quo when it comes to the development of new treatments for patients

Post this

CNS Summit Chairman and Chief Curator, Dr. Amir Kalali, stated, "At CNS Summit, we are proud to support leading startups. The CNS Summit Innovation Showcase is a competitive process with independent judging that showcases the top new startups in the life science ecosystem."

"This award is a testament to the transformative impact of Vivo and the dedication of our team at OmniScience," said Angela Holmes, CEO of OmniScience. "Winning the Innovation Showcase validates our vision of unifying clinical trial data to empower teams with real-time insights that drive faster, smarter decisions. We are honored to be recognized by our peers and remain committed to advancing clinical development for better patient outcomes in neurology and psychiatry and beyond."

The CNS Summit Innovation Showcase is a stage for forward-thinking companies to share solutions that address pressing challenges in clinical development. This year's submissions underwent a rigorous peer-review process, with Vivo being selected as one of the top four finalists based on its innovation, novelty, and potential impact on clinical research. Judges of the summit ultimately awarded Vivo the top position, recognizing its ability to streamline data accessibility and support actionable insights that reduce clinical trial timelines and increase probability of success. Notable organizations in attendance at the 2024 Summit included AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Johnson & Johnson, Novo Nordisk, Pfizer, Roche, and Takeda.

Driving Efficiency in Complex Trials and Addressing the Challenges of Siloed Data in Clinical Trials:

"Clinical trial complexity is skyrocketing, especially in CNS trials, where we're dealing with diverse data types from labs, sensors, digital biomarkers, and imaging," said Michael Bell, PhD, VP of Product at OmniScience, who led the showcase presentation. "Vivo changes the game for biopharma teams, enabling them to access on-demand insights, detect data discrepancies, forecast enrollment timelines, and monitor site, safety, and clinical metrics—all in one unified portal. Our team at OmniScience has drawn on years of experience in clinical data science to bring Vivo to life, and this win reinforces our commitment to accelerating therapeutic development."

Vivo was developed to address the significant hurdles clinical operations teams face in managing siloed data, which impede timely, informed decision-making. During his presentation, Dr. Bell demonstrated how Vivo's genAI capabilities allow teams to ask complex questions—such as identifying operational and safety risks and monitoring data quality and completeness—and receive instant, plain-language answers. Vivo's AI-driven approach enables the delivery of proactive notifications, helping teams make informed adjustments throughout their trials.

Designed with explainability and interpretability at its core, Vivo ensures that every generated insight is supported by clear, traceable rationale grounded in data and clinical context. Its advanced cognitive architecture combines ontological knowledge of trial protocols with domain-specific clinical expertise, enabling qualitative and quantitative reasoning at scale.

"We are proud to be recognized by our peers for Vivo's potential to transform how biopharma approaches clinical trial data," Bell shared. "OmniScience has built a product that empowers study teams and their CROs with the oversight and insights they need to get critical treatments to patients faster."

About the CNS Summit Innovation Showcase:

The CNS Summit Innovation Showcase is an annual opportunity for emerging companies to spotlight their innovative solutions in clinical research. This event brings together technology companies and industry leaders, creating a collaborative environment where groundbreaking ideas meet strategic partners. Through peer review, attendee voting, and independent judging, the showcase rewards innovation that has the potential to accelerate the development of life-changing therapies.

About OmniScience:

OmniScience is a trusted partner to leading life science organizations advancing clinical R&D missions through unparalleled expertise in clinical data science. Our expert team has served biopharma as a data science CRO, developing AI/ML solutions to translate complex clinical trial data into insights.

We believe in a future where all clinical trial data can be unified and translated into knowledge in real time. That's why we created Vivo - your new favorite clinical development colleague.

Improve monitoring and oversight. Make better decisions with higher quality data. Reduce cost. Shorten timelines. If you would like to discuss how we can support your clinical trials, reach us at [email protected] or on LinkedIn.

Media Contact
Carla Holloway, OmniScience, 1 3023790441, [email protected], omniscience.bio

SOURCE OmniScience

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.